These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 28954087)

  • 1. Drug-induced hypersensitivity syndrome after initiation of darunavir and raltegravir.
    Eyer-Silva WA; Freire MAL; Silva GARD
    Rev Soc Bras Med Trop; 2017; 50(4):575-576. PubMed ID: 28954087
    [No Abstract]   [Full Text] [Related]  

  • 2. Post-prandial lipid effects of raltegravir versus darunavir/ritonavir in HIV-1-infected adults commencing combination ART.
    Lee FJ; Marriott D; Bloch M; Richardson R; Mackenzie N; Carr A
    J Antimicrob Chemother; 2016 Apr; 71(4):1127-9. PubMed ID: 26682962
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir.
    Thomas M; Hopkins C; Duffy E; Lee D; Loulergue P; Ripamonti D; Ostrov DA; Phillips E
    Clin Infect Dis; 2017 May; 64(9):1198-1203. PubMed ID: 28369189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Walter M
    MMW Fortschr Med; 2015 Jun; 157 Suppl 2():55. PubMed ID: 26048127
    [No Abstract]   [Full Text] [Related]  

  • 5. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
    Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
    HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Attending to life style and comorbidities. Comprehensive management of HIV patients].
    MMW Fortschr Med; 2016 Jun; 158 Suppl 1():52-3. PubMed ID: 27259888
    [No Abstract]   [Full Text] [Related]  

  • 7. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
    Calza L; Danese I; Colangeli V; Manfredi R; Magistrelli E; Verucchi G; Conti M; Motta R; Viale P
    Infect Dis (Lond); 2015 Sep; 47(9):625-36. PubMed ID: 25875396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Predictive factors of clinically significant drug-drug interactions among regimens based on protease inhibitors, non-nucleoside reverse transcriptase inhibitors and raltegravir].
    Cervero M; Torres R; Jusdado JJ; Pastor S; Agud JL
    Med Clin (Barc); 2016 Apr; 146(8):339-45. PubMed ID: 26971988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rate of DRESS Syndrome With Raltegravir and Role of the HLA-B*53: 01 Allele.
    Lefebvre M; Walencik A; Allavena C; Billaud E; Kassi A; Cesbron A; Joyau C; Secher S; Ruellan AL; Raffi F;
    J Acquir Immune Defic Syndr; 2020 Dec; 85(4):e77-e80. PubMed ID: 33136758
    [No Abstract]   [Full Text] [Related]  

  • 10. Raltegravir-induced drug reaction with eosinophilia and systemic symptoms syndrome in a child.
    Scaggs FA; Aziz MS; Palmisano EL; Mahdavinia M; Raikar SS; Logan LK
    Ann Allergy Asthma Immunol; 2016 Dec; 117(6):719-721. PubMed ID: 28073704
    [No Abstract]   [Full Text] [Related]  

  • 11. [Use of raltegravir in pregnant HIV-1 infected women: experience in different clinical scenarios].
    Cecchini D; Martinez M; Morganti L; Rodriguez C
    Enferm Infecc Microbiol Clin; 2014 Nov; 32(9):616-8. PubMed ID: 24556267
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical relevance of cross-reactivity between darunavir and trimethoprim-sulfamethoxazole in HIV-infected patients.
    Lin KY; Hung CC
    AIDS; 2015 Oct; 29(16):2213-4. PubMed ID: 26544585
    [No Abstract]   [Full Text] [Related]  

  • 13. Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient.
    Vento S; Vallone A
    AIDS Patient Care STDS; 2008 Nov; 22(11):841-2. PubMed ID: 19025477
    [No Abstract]   [Full Text] [Related]  

  • 14. Raltegravir is safely used with long-term viral suppression for HIV-infected patients on hemodialysis: a pharmacokinetic study.
    Yanagisawa K; Nagano D; Ogawa Y; Uchiumi H; Shigehara T; Saruki K; Handa H; Araki T; Yamamoto K; Nojima Y
    AIDS; 2016 Mar; 30(6):970-2. PubMed ID: 26959356
    [No Abstract]   [Full Text] [Related]  

  • 15. A case of late presentation of darunavir-related cholestatic hepatitis.
    Yancheva N; Tzonev R
    Int J STD AIDS; 2019 May; 30(6):620-622. PubMed ID: 30722751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of antiretroviral regimens including raltegravir to treat HIV-infected patients with hemophilia.
    Xiao H; Xue Y; Gu S; Wang J; Sun H; Lu H
    Biosci Trends; 2016 Feb; 10(1):42-6. PubMed ID: 26911541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life improvement in HIV-1 patients treated with raltegravir in a real-life observational study: RACING.
    Spire B; Nait-Ighil L; Pugliese P; Poizot-Martin I; Jullien V; Marcelin AG; Billaud E
    HIV Clin Trials; 2017 Jan; 18(1):1-16. PubMed ID: 28125951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of raltegravir use with long-term health outcomes in HIV-infected patients: an observational post-licensure safety study in a large integrated healthcare system.
    Horberg MA; Oakes AH; Hurley LB; Towner WJ; Chao CR; Silverberg MJ; Chantra JQ; Ellis CG; Quesenberry CP
    HIV Clin Trials; 2018 Oct; 19(5):177-187. PubMed ID: 30370835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.
    Blonk MI; Colbers AP; Hidalgo-Tenorio C; Kabeya K; Weizsäcker K; Haberl AE; Moltó J; Hawkins DA; van der Ende ME; Gingelmaier A; Taylor GP; Ivanovic J; Giaquinto C; Burger DM; ;
    Clin Infect Dis; 2015 Sep; 61(5):809-16. PubMed ID: 25944344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine.
    Assoumou L; Racine C; Fellahi S; Lamaziere A; Farabos D; Beniguel L; Bastard JP; Feve B; Gibowski S; Katlama C; Costagliola D; Capeau J
    AIDS; 2020 Oct; 34(12):1859-1862. PubMed ID: 32773470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.